Clinical Trial Update: A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing safety and efficacy of ABT-089 in children with Attention-Deficit/Hyperactivity Disorder has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• ABT-089

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Attention-Deficit/Hyperactivity Disorder | Phase 2 | Status: COMPLETED